Perspective Therapeutics, Inc. (NYSE:CATX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Perspective Therapeutics, Inc. (NYSE:CATX) have been assigned a consensus recommendation of “Moderate Buy” from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $15.14.

Several brokerages have recently weighed in on CATX. Truist Financial started coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a “buy” rating and a $21.00 price target for the company. Wedbush reissued an “outperform” rating and set a $11.00 target price (down previously from $20.00) on shares of Perspective Therapeutics in a research report on Thursday, November 21st. UBS Group started coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $20.00 price target for the company. Oppenheimer reduced their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a research note on Monday, September 9th.

Perspective Therapeutics Price Performance

CATX opened at $4.36 on Friday. Perspective Therapeutics has a fifty-two week low of $2.28 and a fifty-two week high of $19.05. The company’s 50 day moving average price is $10.60 and its two-hundred day moving average price is $12.27.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, hitting the consensus estimate of ($0.21). The company had revenue of $0.37 million for the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. Equities research analysts predict that Perspective Therapeutics will post -0.87 EPS for the current year.

Insider Activity at Perspective Therapeutics

In other news, CFO Jonathan Robert Hunt purchased 12,829 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The shares were acquired at an average cost of $3.82 per share, with a total value of $49,006.78. Following the purchase, the chief financial officer now owns 48,800 shares in the company, valued at $186,416. This represents a 35.66 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Johan M. Spoor purchased 14,500 shares of the business’s stock in a transaction on Monday, November 25th. The stock was purchased at an average price of $3.78 per share, for a total transaction of $54,810.00. Following the acquisition, the chief executive officer now owns 152,072 shares of the company’s stock, valued at approximately $574,832.16. This represents a 10.54 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased 33,595 shares of company stock worth $126,625 in the last quarter. Company insiders own 3.52% of the company’s stock.

Institutional Trading of Perspective Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. FMR LLC lifted its stake in shares of Perspective Therapeutics by 3,994.9% in the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after buying an additional 5,370,392 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Perspective Therapeutics by 34.6% in the 1st quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock worth $21,158,000 after acquiring an additional 4,566,356 shares during the last quarter. Nicholson Wealth Management Group LLC bought a new position in Perspective Therapeutics in the 3rd quarter valued at about $21,390,000. State Street Corp boosted its stake in Perspective Therapeutics by 119.6% during the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after purchasing an additional 1,192,812 shares during the last quarter. Finally, Hills Bank & Trust Co bought a new stake in Perspective Therapeutics during the 3rd quarter worth approximately $13,722,000. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.